Although lowering blood pressure (BP) reduces aortic stiffness, achieving the recommended BP goal can be difficult. Recent studies have shown that short-term use of statins can reduce BP significantly. To determine the long-term effects of statins on BP and aortic stiffness, a single-blind randomized prospective study was performed on 85 hyperlipidaemic hypertensive patients whose BP was insufficiently controlled by antihypertensive therapy. Every 3 months, aortic stiffness was assessed by measuring pulse wave velocity (PWV). Patients were randomly allocated to groups treated with pravastatin, simvastatin, fluvastatin, or a nonstatin antihyperlipidaemic drug. No significant differences in patient characteristics, kinds of antihypertensive drugs, BP, ankle brachial index, PWV, or serum lipid, creatinine, or C-reactive protein levels were found between the four groups at the start of the study. During the 12-month treatment period, PWV did not change in the pravastatin group or nonstatin group, but it was transiently reduced in the simvastatin group and significantly decreased in the fluvastatin group, even though the doses of the statins used in this study were lower than the usually prescribed dose. All four antihyperlipidaemic drugs significantly decreased serum cholesterol levels without affecting BP, ankle brachial index, or serum triglyceride levels. The Creactive protein serum levels decreased significantly in the three statin groups but not in the nonstatin group. These results suggest that long-term use of fluvastatin by hyperlipidaemic hypertensive patients is associated with a significant reduction in aortic stiffness without any effect on BP.
Introduction
Noninvasive assessment of aortic stiffness by measuring pulse wave velocity (PWV) along the aortoiliac pathway can be used to predict all-cause and cardiovascular-related mortality in hypertensive patients. [1] [2] [3] [4] We previously demonstrated that longterm, successful control of blood pressure (BP) with a target BP of o130/85 mmHg significantly decreases the PWV in hypertensive patients. 5 However, achieving this BP target is difficult for the hypertensive patients; some are unable to sufficiently control their BP and exhibit a high PWV, despite the best efforts of their physicians. Recent studies have shown that statins can be used to reduce BP in hypertensive patients with hypercholesterolaemia. [6] [7] [8] The mechanism of the reduction of BP by statins in hypertensive hyperlipidaemic patients involves the activation of endothelial nitric oxide synthase, 9 the downregulation of angiotensin II type 1 receptors, 10 and a reduction in the vascular production of reactive oxygen species. 11 In addition, the long-term administration of statins has been shown to inhibit the progression of aortic stenosis 12 and to reduce aortic stiffness, as assessed by PWV, in normotensive patients with hypercholesterolaemia. 13, 14 Therefore, long-term statin administration may improve BP control and PWV in patients with uncontrolled hypertension and high serum cholesterol levels. However, a recent study reported that 12-week atorvastatin treatment worsened PWV in hypertensive hyperlipidaemic patients. 15 The purpose of the present study was to determine the long-term effects of statins on BP control and PWV in hypertensive hyperlipidaemic patients undergoing antihypertensive therapy. Since recent in vivo studies in rabbits 16 and in vitro data [17] [18] [19] have indicated that hydrophilic and lipophilic statins have different effects on apoptosis, proliferation of vascular smooth muscle cells, and collagen production by vascular smooth muscle cells, in the present study we evaluated the effects of a hydrophilic drug, pravastatin, and two lipophilic drugs, simvastatin and fluvastatin, on the PWV of hypertensive patients with high serum cholesterol levels.
Subjects and methods

Subjects and study design
A total of 88 hypertensive patients who had consecutively attended the outpatient hypertension clinic at the Kawasaki Ida Municipal Hospital and had a baseline PWV measurement of arterial stiffness were enrolled in a single-blind randomized prospective study. Patients with cardiovascular disease or peripheral arterial disease (ankle-brachial index (ABI) o0.9) were excluded from the study. No patients with any form of secondary hypertension based on the results of classic laboratory and radiology tests were included in the study. All hypertensive patients had been previously treated with antihypertensive drugs and had an insufficiently controlled BP that had not reached the BP goal of o130/85 mmHg. At the time of enrolment, each patient was assigned to a treatment group by selecting a sealed envelope containing a paper with the name of one of the treatment drugs. In this manner, 22 patients were randomly assigned to each treatment group: pravastatin (10 mg/day), simvastatin (5 mg/day), fluvastatin (20 mg/day), and a nonstatin antihyperlipidaemic drug (clofibrate (750 mg/ day) or probucol (500 mg/day)). The dosing choices at the beginning of the study were made based on records in our hospital showing that Asian patients whose serum TC levels were reduced below 220 mg/ dl had received pravastatin 10.2 mg/day (n ¼ 221), simvastatin 5.1 mg/day (n ¼ 163), or fluvastatin 21.2 mg/day (n ¼ 106). To achieve the target level of serum TC o220 mg/dl, every 5 mg/day of statins or every 250 mg/day of nonstatin antihyperlipidaemic drug were added on. The patient's physicians were unaware of their PWV levels during the 12-month treatment period. Drug compliance during the study was assessed on the basis of the patients' selfreports, and one patient in the pravastatin group and two patients in the nonstatin antihyperlipidaemic drug group were subsequently excluded from the study because of poor drug compliance. Each subject provided their informed consent, and the study was approved by the review board of the Kawasaki Ida Municipal Hospital.
Measurements
Every 3 months during the 12-month period of the study, the PWV, ABI, heart rate (HR), and BP of each patient were determined using a pulse pressure analyzer (model: BP-203RPE; Nihon Colin, Tokyo, Japan) according to previously described methods. 5, 20 Briefly, pulse waves were recorded using sensors placed on the right brachial artery and both posterior tibial arteries. Electrocardiograms were obtained using electrodes placed at two points on the left arm and one point on the right arm. The time between the wave front of the brachial waveform and the wave front of the posterior tibial waveform was measured as the time between the brachium and ankle (DT ba ). The distance between the right brachial artery and the posterior tibial artery was calculated according to the patient's height. The length of the path from the suprasternal notch to the brachium (L b ) was estimated using superficial measurements and the following equation: L b ¼ 0.2195 Â height of the patient (cm)À2.0734. The length of the path from the suprasternal notch to the ankle (L a ) was estimated using superficial measurements and the following equation: L a ¼ 0.8129 Â height of the patient (cm) þ 12.328. Finally, the PWV between the brachium and the ankle (baPWV) was calculated using the following equation: (L a ÀL b )/DT ba . The baPWV values measured using this method are significantly correlated with the carotid-femoral PWV 21 and aortic PWV measured using the catheter method, 22 with high correlation coefficients of 0.81 and 0.87, respectively. However, the baPWV, which includes a smaller artery, is generally higher than the carotid-femoral PWV because wave velocity is inversely proportional to the square root of the vessel's diameter. In the present study, the best 10 consecutive pulses were analysed, and the average baPWV was recorded as the PWV. The baPWV was measured when the patients' HR was stable at 60-80 beats/min after the patient had rested for a minimum of 5 min. Two measurements were performed on each leg, and the average values were used in the analysis. Values are expressed in centimetres per second. The coefficient of variation of the PWV was less than 5%.
Venous blood samples were obtained on the same days as the PWV measurements; the blood samples were drawn in the morning after an overnight fast. Total cholesterol (TC), triglyceride (TG), creatinine, and C-reactive protein (CRP) concentrations were measured using standard methods. High-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels were determined using commercially available kits (Wako Pure Chemical, Osaka, Japan).
Statistical analyses
Fisher's exact test was used to analyse the gender and the frequency of the patients' characteristics, except for age and body mass index, which were analysed using the Mann-Whitney U-test. Differences in the numbers of patients taking antihypertensive drugs were tested using Fisher's exact test. The changes in biological parameters and the differences among the groups were analyzed using a two-way analysis of variance for repeated measures and the Newmann-Keuls post hoc test. A value of Po0.05 was considered significant. Data were presented as the means7s.e.m. The number of patients in the present study was sufficient for the estimated required sample size (15.6 in each group) with an a-error of 0.05 and a power of 0.8. Table 1 shows that the age, gender distribution, body mass index, smoking ratio, diabetes mellitus and proteinuria complications, and serum concentrations of creatinine were similar in the four groups at the start of the study. During the 12-month treatment, no significant changes in body mass index or serum creatinine concentrations were observed in any of the groups. At the start of the study, all patients were receiving some kind of antihypertensive drugs, such as calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha-blockers, beta-blockers, and diuretics, alone or in combination. The distributions of the antihypertensive drugs being taken in each group were similar among the four groups. Table 2 shows the changes in systolic and diastolic BP during the 12-month treatment period. At the start of the treatment period, the systolic/diastolic BPs were similar among the four groups. Compared to the 0-month evaluation, a significant decrease in systolic BP was observed in the simvastatin group at the 3-month evaluation, and a significant increase in diastolic BP was observed in the nonstatin group at the 9-month evaluation. No other differences among the four groups and no other significant changes during the 12-month treatment period in each group were observed.
Results
Patient characteristics
Blood pressure
PWV and ABI Figure 1 shows the changes in PWV in the four groups during the 12-month treatment period. At the start of the treatment period, the PWVs of the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar and averaged 17807100, 1792766, 1788785, and 17867129 cm/s, respectively. The PWVs of the pravastatin and nonstatin groups did not change during the 12-month treatment period. After 3 months, however, the PWVs of the simvastatin and fluvastatin groups significantly decreased to 1680755 and 1686779 cm/s, respec- tively. Thereafter, the PWV of the simvastatin group returned to its basal level, but the reduced PWV of the fluvastatin group was maintained until the end of the treatment period. At the start of the treatment period, the ABIs of the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar and averaged 1.1570.02, 1.0770.03, 1.0970.03, and 1.1170.04, respectively. The ABI did not change in any of the groups during the treatment period. Figure 2 shows the changes in the serum TC concentrations during the 12-month treatment period. At the start of the treatment period, the serum TC concentrations of the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar and averaged 6.7270. 16 Figure 3 shows the changes in the serum LDL concentrations during the 12-month treatment period. At the start of the treatment period, the serum LDL concentrations of the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar and averaged 3.8870.13, 3.9670.16, 4.1670.18, and 3.6570.10 mmol/l, respectively. After 3 months, the serum LDL concentrations of the simvastatin and fluvastatin groups had significantly decreased to 3.5270.13 and 3.5470.16 mmol/l, respectively; these reductions were maintained until the end of the treatment period. The reductions in serum LDL concentrations in the simvastatin and fluvastatin groups were similar. The serum LDL concentrations in the pravastatin and nonstatin groups did not change during the treatment period. At the start of the treatment period, the serum HDL concentrations of the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar and averaged 1.6870.13, 1.6370.05, 1.7170.13, and Serum concentration of C-reactive protein Figure 4 shows the changes in the serum CRP concentrations during the 12-month treatment period. At the start of the treatment period, the serum CRP concentrations of the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar and averaged 26.9710.0, 22.374.6, 31.5710.0, and 23.173.8 nmol/l, respectively. After 6 months, the serum CRP concentration of the simvastatin group had significantly decreased to 12.374.6 nmol/l; this reduction was maintained until the end of the treatment period. After 9 months, the serum CRP concentrations of the pravastatin and fluvastatin groups significantly decreased to 9.270.8 and 7.771.5 nmol/l, respectively; these reductions were maintained until the end of the treatment period. In the nonstatin group, however, the serum CRP concentration did not change during the treatment period.
Serum lipid concentrations
Discussion
Previous studies have reported a BP-lowering effect of statins in hyperlipidaemic hypertensive patients who were not taking any antihypertensive drugs 6 and who had already received antihypertensive therapy. 7, 8 However, the results of the present study clearly demonstrated that long-term use of pravastatin, simvastatin, fluvastatin, and nonstatin antihyperlipidaemic drug had no additional effect on BP but significantly decreased the serum TC levels in hypertensive patients with high serum TC levels and insufficiently controlled BP despite antihypertensive therapy. This discrepancy may be attributable to the longer treatment period in the present study: the patients in previous studies received statins for only 3 or 4 months, whereas our patients received statins for 12 months. The fact that the patients' BP did not change during the 12-month treatment period, except for a transient decrease at the 3-month evaluation in the simvastatin group, suggested that hydrophilic and lipophilic statins do not affect brachial artery BP over a 6-month treatment period. It is possible, however, that their central aortic systolic pressure may have fallen during fluvastatin therapy because there was a significant decrease in PWV. Alternatively, antihypertensive therapy may affect the BP-lowering effect of statins. In previous studies, 7, 8 70-100% of patients received angiotensin-converting enzyme inhibitors, whereas only 32-36% of the patients in the present study had taken angiotensin-converting enzyme inhibitors, and possible interaction with angiotensin-converting enzyme inhibitors may play an important role in the BP-lowering effect of statins.
The reductions in serum TC levels in the pravastatin, simvastatin, fluvastatin, and nonstatin groups were similar. During the 12-month follow-up period, a significant decrease in PWV was observed in the groups treated with the lipophilic drug fluvastatin, but not in the groups treated with the hydrophilic drug pravastatin or the nonstatin drugs. Another lipophilic drug, simvastatin, elicited a significant but transient fall in PWV at 3 months. These findings are consistent with the results of previous in vitro and ex vivo studies. Fluvastatin and simvastatin, but not pravastatin, decreased proliferation 17, 23, 24 and increased apoptosis 17 by human vascular smooth muscle cells. Fluvastatin decreased the number of vascular smooth muscle cells in hyperlipidaemic rabbits without increasing interstitial collagen content, whereas pravastatin increased both the number of vascular smooth muscle cells and interstitial collagen content. 16 In addition, lipophilic statins, such as atorvastatin, simvastatin, or lovastatin induced apoptosis by rat vascular smooth muscle cells, but the hydrophilic drug pravastatin did not. 18 Thus, hydrophilic and lipophilic statins may have different effects on vascular smooth muscle cell accumulation and collagen production, independent of their cholesterol-lowering effect. The results of the present study provide important in vivo evidence that long-term treatment with lipophilic statins, but not with the hydrophilic drug pravastatin, can improve aortic stiffness independently of their potential BP-lowering or antihyperlipidaemic effects.
Both simvastatin and fluvastatin decreased serum LDL and CRP levels similarly, but only simvastatin had decreased serum HDL levels at the 6-and 9-month evaluations. Because the results of larger simvastatin trials have demonstrated mild HDL elevations, the serum HDL level in the simvastatin group may be related to limitations inherent in the small sample size or to responses specific to the population studied, which had a predominance of women (67%) and relatively high HDL levels (mean 1.63-1.84 mmol/l) for a population aged 60 years. While the decrease in PWV in the simvastatin group at the 3-month evaluation was transient and PWV subsequently returned to its basal level, the reduction in PWV at 3 months in the fluvastatin group was maintained until the end of the treatment period. Antioxidant activities may have contributed to the different effects of simvastatin and fluvastatin on PWV. Vascular superoxide production promotes the development and progression of atherosclerosis through endothelial dysfunction, 25 which is inhibited by the antioxidant effects of statins. 26 Recent in vivo 27, 28 and in vitro 29, 30 studies have shown that fluvastatin has more potent antioxidative effects than other statins, including pravastatin, simvastatin, cerivastatin, and atorvastatin, although simvastatin also has some antioxidant effect. 31 Thus, the powerful antioxidant properties of fluvastatin may have contributed to the reduction in PWV.
The nonstatin antihyperlipidaemic drugs reduced the serum TC levels without reducing the serum HDL levels to the same degree as fluvastatin, and some patients in the nonstatin group received probucol, which has an antioxidant activity similar to that of fluvastatin. 27 Nevertheless, the PWV levels of these patients did not decrease during the 12-month treatment period. The serum LDL and CRP levels did not decrease significantly in the nonstatin group. LDL is well known to play an important role in the mechanism of atherogenesis, 32 and since recent studies have suggested that inflammatory mediators, including CRP, are involved in the development and progression of atherosclerosis, 33, 34 a reduction in serum LDL and CRP levels may also have contributed to the reduction in PWV.
A recent study has shown that treatment with a lipophilic drug, atorvastatin, for 12 weeks unexpectedly increased the PWV, despite a more rapid and powerful decrease in serum cholesterol levels than produced by fluvastatin or simvastatin. 15 Radical reductions in lipid levels may lead to a transient stiffening of arterial walls, because vessels are composed of both soft (lipid-containing) and rigid (sclerotic) tissue. In addition, the ability of fluvastatin and simvastatin to inhibit proliferation and cholesterol biosynthesis in human arterial myocytes is approximately 10-25 times greater than that of atorvastatin. 24 Therefore, fluvastatin and simvastatin may be safer and more effective for softening arterial walls than atorvastatin.
The doses of statins were chosen based on records in our hospital, and our patients' serum TC levels were significantly reduced below 220 mg/dl regardless of which statin they were given. However, since the doses were lower than those customarily tested in clinical trials, if our patients had been treated with the usually prescribed doses of pravastatin and simvastatin, a similar fall in PWV might have been observed. Moreover, higher doses of statins may elicit a decrease in BP. Further studies using higher doses of statins are needed to confirm the different effects of statins on BP and PWV observed in the present study.
In conclusion, the long-term administration of statins did not cause any additional reduction in the BP of hypertensive patients who had high serum cholesterol levels and BP insufficiently controlled by antihypertensive therapy. However, lipophilic statins with antioxidant activity, such as fluvastatin, significantly reduced the PWV, which is an independent predictor of future cardiovascular events in such patients. When the BP fails to reach the target values in hypertensive hyperlipidaemic patients despite the best efforts of physicians, long-term administration of fluvastatin can be recommended to decrease the risk of cardiovascular events.
